Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 9/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21961925 | 0.85 | SIGMAR1 (0.71) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL1259602 | 0.85 | SIGMAR1 (0.71) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL2225221 | 0.84 | PRMT6 (0.62) | SIGMAR1FAAHTDP1HRH3HTR2A | |
| Bromide SCHEMBL1259195 | 0.84 | SIGMAR1 (0.69) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL26149604 | 0.82 | SMN1; SMN2 (0.64) | SIGMAR1FAAHTDP1HRH3 | |
| SCHEMBL593734 | 0.79 | SIGMAR1 (0.62) | SIGMAR1CXCR4MEN1KMT2AHRH3 | |
| SCHEMBL807251 | 0.79 | NCF1 (0.66) | SIGMAR1CXCR4FAAHHRH3HTR2A | |
| SCHEMBL21799527 | 0.79 | PRMT6 (0.72) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL6858101 | 0.79 | SIGMAR1 (0.62) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL8879213 | 0.79 | SIGMAR1 (0.62) | SIGMAR1CXCR4MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231619-B1 | INHIBITORS OF STEAROYL-COA DESATURASE | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| CN-101896473-B | Inhibitors of stearoyl-coa desaturase | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| CN-101896473-A | Inhibitors of stearoyl-coa desaturase | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| EP-2231619-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010036814-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| CN-101686979-A | The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces | JANSSEN PHARMACEUTICA NV | 2010-03-31 | — | — | CN | disclosed |
| EP-2164493-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-03-24 | — | — | EP | disclosed |
| US-7652013-B2 | Inhibitors of stearoyl-CoA desaturase | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009074487-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | GILLESPIE PAUL | 2009-06-11 | — | — | US | disclosed |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008153752-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | SIGMAR1 2689/4885CXCR4 4614/4885FAAH 191/4885 |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | SIGMAR1 1261/4885CXCR4 1124/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.